Sandoz Picks Hexal’s Hometown For Generics Division Global Headquarters
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ generics division will move to Holzkirchen, Germany, the home of Hexal, as part of the integration of that company and U.S-based Eon. Acquisition of the two generic firms is expected to close in the second half of 2005.
You may also be interested in...
Eon CEO Hampl Will Head Sandoz’ U.S. Operations Following Acquisition
Eon Labs CEO Bernhard Hampl will become head of Sandoz' U.S. operations following Novartis' acquisition of Eon
Novartis Boosts Sandoz Generic Business With Acquisition Of Eon, Hexal
Addition of U.S., German companies will make Sandoz the global leader in generic sales, with combined 2004 pro forma revenues of $5.1 bil., Novartis says. Acquisition will enable Sandoz to become the "preferred partner" for "authorized" generic deals and to play a leading role in development of follow-on biologics.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.